Bavarian Nordic

Update in progress

BAVA.CO (Copenhagen)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Bavarian Nordic A/S develops, manufactures, and supplies vaccines. It offers non-replicating smallpox and monkeypox vaccines (IMVAMUNE/IMVANEX/JYNNEOS), rabies vaccines (Rabipur/RabAvert), a tick-borne encephalitis vaccine (Encepur), the oral cholera vaccine Vaxchora, and the oral typhoid vaccine Vivotif/Typhoral. It is advancing MVA-BN WEV for encephalitis viruses (phase 2). Headquartered in Hellerup, Denmark, it operates globally.

Company score

Sentiment: 1.16; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.07; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 1.41; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.47; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.54; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.85; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive